It had posted net profit of Rs 33.46 crore for the April- June period last fiscal.
The company's total income from operations rose to Rs 223.71 crore for the quarter under consideration, as against Rs 209.96 crore for the year-ago period.
In a separate filing on the BSE, Natco Pharma said its Board of Directors has approved the sub-division of face value of equity shares from Rs 10 each to that of Rs 2 each and enhancement of limits of borrowing powers.